Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

REVA Medical Closes Financing

November 20, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that the financing transaction approved by the Company’s shareholders at the Special Meeting of Stockholders held in Sydney, Australia on October 31, 2014, has been successfully…

Isis Pharmaceuticals, Inc. Release: ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca PLC At

November 20, 2014 – 5:00 pm | Edit Post

CARLSBAD, Calif., Nov. 20, 2014 /PRNewswire/ –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from two drugs in its anti-cancer franchise will be presented by researchers at AstraZeneca in three presentations at the 26th European Organization for Research and Treatment of Cancer…

West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More

November 20, 2014 – 2:21 pm | Edit Post

Snow? What snow? The only thing piling up at astonishing rates on the West Coast this week is biotech news. Up in Seattle, the Fred Hutchinson Cancer Research Center has unveiled its new president,…

[[Click headline to continue reading.]]

Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast

November 20, 2014 – 2:09 pm | Edit Post

NEW YORK and SAN DIEGO, Nov. 20, 2014 /PRNewswire/ – Cytori Therapeutics (NASDAQ: CYTX), today announced that President and CEO Marc Hedrick, M.D. will present live at VirtualInvestorConferences.com on December 4, 2014.

DATE:   Thursday, December 4, 2014 TIME:    11:15 am PT / 2:15 pm ET LINK:     Click here or paste this URL into your browser’s address bar: http://bit.ly/1B2KGaL

It is recommended that investors pre-register to save time and receive event updates.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the association’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

“In the past few months, we have substantially focused operations and reprioritized Cytori’s key value drivers. Our top corporate goals are to grow the clinical pipeline in the United States, further expand our government and corporate partnering efforts and bring our commercial activities to positive cash flow,” said Dr. Hedrick. “We invite our investors and supporters to connect and learn more about these recent changes. Also, we will provide an update on the new regenerative medicine law in Japan and what it means for Cytori, and discuss our plan for rebuilding value in Cytori for our shareholders and for the patients who can benefit from Cytori Cell Therapy.”

Recent Company Highlights

BARDA, a branch of the U.S. government, executed a contract extension option with Cytori to significantly expand funded research and development activities for a medical countermeasure to be used in the treatment of thermal burns and radiation injury.
Cytori will complete six-month patient follow-up from the U.S. ATHENA trial for heart failure due to ischemic heart disease and expects to complete this analysis in 1Q2015.
Received FDA approval to begin a U.S. IDE trial of Cytori Cell Therapy on patients with knee osteoarthritis with enrollment scheduled to begin in early in 2015.
Completed enrollment and preliminary analysis of a 20-patient E.U. feasibility study for use of Cytori Cell Therapy in the treatment of patients with anterior cruciate ligament (ACL) injuries.
Reported publication in the Annals of the Rheumatic Diseases of the results of six-month outcomes in a 12-patient feasibility study of the use of Cytori Cell Therapy in patients with scleroderma-associated hand disease.About Cytori Therapeutics Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat a variety of medical conditions. Multiple scientific publications suggest that Cytori Cell Therapy and ADRCs improve blood flow, moderate the inflammatory response and facilitate wound repair. As a result, we believe these cells can be applied with success across multiple disease states. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® System product family. For more information: visit www.cytori.com or follow on Twitter www.twitter.com/cytori.

About VirtualInvestorConferences.com Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network.

Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts, including statements regarding our ability to provide updated timelines for completion of enrollment of the osteoarthritis clinical trial, our ability to obtain expanded contract options with BARDA, our ability to complete data review associated with six-month patient follow-up from the U.S. ATHENA trial, those regarding our belief in the safety and feasibility in using Cytori Cell Therapy for treatment of scleroderma-associated hand disease and treatment of anterior cruciate ligament (ACL) tears and therapeutic potential to accelerate healing and recovery with Cytori Cell Therapy for the treatment of such conditions, our expectation of continuing demand from investigator initiated trial customers, are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, pre-clinical and regulatory uncertainties, the quality of data supporting execution of BARDA contract options, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports.

There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.
SOURCE Cytori Therapeutics

Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast

November 20, 2014 – 2:09 pm | Edit Post

NEW YORK and SAN DIEGO, Nov. 20, 2014 /PRNewswire/ – Cytori Therapeutics (NASDAQ: CYTX), today announced that President and CEO Marc Hedrick, M.D. will present live at VirtualInvestorConferences.com on December 4, 2014.

DATE:   Thursday, December 4, 2014 TIME:    11:15 am PT / 2:15 pm ET LINK:     Click here or paste this URL into your browser’s address bar: http://bit.ly/1B2KGaL

It is recommended that investors pre-register to save time and receive event updates.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the association’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

“In the past few months, we have substantially focused operations and reprioritized Cytori’s key value drivers. Our top corporate goals are to grow the clinical pipeline in the United States, further expand our government and corporate partnering efforts and bring our commercial activities to positive cash flow,” said Dr. Hedrick. “We invite our investors and supporters to connect and learn more about these recent changes. Also, we will provide an update on the new regenerative medicine law in Japan and what it means for Cytori, and discuss our plan for rebuilding value in Cytori for our shareholders and for the patients who can benefit from Cytori Cell Therapy.”

Recent Company Highlights

BARDA, a branch of the U.S. government, executed a contract extension option with Cytori to significantly expand funded research and development activities for a medical countermeasure to be used in the treatment of thermal burns and radiation injury.
Cytori will complete six-month patient follow-up from the U.S. ATHENA trial for heart failure due to ischemic heart disease and expects to complete this analysis in 1Q2015.
Received FDA approval to begin a U.S. IDE trial of Cytori Cell Therapy on patients with knee osteoarthritis with enrollment scheduled to begin in early in 2015.
Completed enrollment and preliminary analysis of a 20-patient E.U. feasibility study for use of Cytori Cell Therapy in the treatment of patients with anterior cruciate ligament (ACL) injuries.
Reported publication in the Annals of the Rheumatic Diseases of the results of six-month outcomes in a 12-patient feasibility study of the use of Cytori Cell Therapy in patients with scleroderma-associated hand disease.About Cytori Therapeutics Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat a variety of medical conditions. Multiple scientific publications suggest that Cytori Cell Therapy and ADRCs improve blood flow, moderate the inflammatory response and facilitate wound repair. As a result, we believe these cells can be applied with success across multiple disease states. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® System product family. For more information: visit www.cytori.com or follow on Twitter www.twitter.com/cytori.

About VirtualInvestorConferences.com Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network.

Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts, including statements regarding our ability to provide updated timelines for completion of enrollment of the osteoarthritis clinical trial, our ability to obtain expanded contract options with BARDA, our ability to complete data review associated with six-month patient follow-up from the U.S. ATHENA trial, those regarding our belief in the safety and feasibility in using Cytori Cell Therapy for treatment of scleroderma-associated hand disease and treatment of anterior cruciate ligament (ACL) tears and therapeutic potential to accelerate healing and recovery with Cytori Cell Therapy for the treatment of such conditions, our expectation of continuing demand from investigator initiated trial customers, are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, pre-clinical and regulatory uncertainties, the quality of data supporting execution of BARDA contract options, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports.

There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.
SOURCE Cytori Therapeutics

Grant Gives New Breath to Patients Suffering from Severe Pulmonary Hypertension

November 20, 2014 – 12:09 pm | Edit Post

UC San Diego Health System is a world leader in chronic thromboembolic pulmonary hypertension (CTEPH), and now with a $7.6 million grant, has helped launch the first national CTEPH registry to improve best practices and patient care.

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group